GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dendreon Corp (FRA:DNR) » Definitions » Cyclically Adjusted PS Ratio

Dendreon (FRA:DNR) Cyclically Adjusted PS Ratio : (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Dendreon Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Dendreon Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Dendreon's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dendreon Cyclically Adjusted PS Ratio Chart

Dendreon Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dendreon Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Mar15
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dendreon's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Dendreon's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dendreon's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dendreon's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dendreon's Cyclically Adjusted PS Ratio falls into.



Dendreon Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Dendreon's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2014 is calculated as:

For example, Dendreon's adjusted Revenue per Share data for the three months ended in Sep. 2014 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=0.367/100.4278*100.4278
=0.367

Current CPI (Sep. 2014) = 100.4278.

Dendreon Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200412 0.001 80.290 0.001
200503 0.001 81.555 0.001
200506 0.001 82.062 0.001
200509 0.001 83.876 0.001
200512 0.001 83.032 0.001
200603 0.000 84.298 0.000
200606 0.001 85.606 0.001
200609 0.001 85.606 0.001
200612 0.001 85.142 0.001
200703 0.001 86.640 0.001
200706 0.005 87.906 0.006
200709 0.001 87.964 0.001
200712 0.000 88.616 0.000
200803 0.000 90.090 0.000
200806 0.000 92.320 0.000
200809 0.000 92.307 0.000
200812 0.000 88.697 0.000
200903 0.000 89.744 0.000
200906 0.000 91.003 0.000
200909 0.000 91.120 0.000
200912 0.000 91.111 0.000
201003 0.000 91.821 0.000
201006 0.017 91.962 0.019
201009 0.109 92.162 0.119
201012 0.133 92.474 0.144
201103 0.132 94.283 0.141
201106 0.229 95.235 0.241
201109 0.319 95.727 0.335
201112 1.047 95.213 1.104
201203 0.421 96.783 0.437
201206 0.430 96.819 0.446
201209 0.404 97.633 0.416
201212 0.435 96.871 0.451
201303 0.344 98.209 0.352
201306 0.366 98.518 0.373
201309 0.334 98.790 0.340
201312 0.358 98.326 0.366
201403 0.324 99.695 0.326
201406 0.393 100.560 0.392
201409 0.367 100.428 0.367

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dendreon  (FRA:DNR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Dendreon Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Dendreon's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dendreon (FRA:DNR) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Dendreon Corp is a Delaware corporation. The Company is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE(r) (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The Other potential product candidates we have under development include our investigational active cellular immunotherapy, DN24-02, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. In addition, the Company has developed an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.

Dendreon (FRA:DNR) Headlines

No Headlines